(UIMI) UBS (Lux) Fund Solutions - Ratings and Ratios
Equities, Emerging Markets, Index, ETF, USD
Dividends
| Dividend Yield | 2.30% |
| Yield on Cost 5y | 2.93% |
| Yield CAGR 5y | 6.06% |
| Payout Consistency | 93.5% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 14.8% |
| Value at Risk 5%th | 22.5% |
| Relative Tail Risk | -7.79% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | 11.73 |
| CAGR/Max DD | 0.54 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.088 |
| Beta | 0.194 |
| Beta Downside | 0.472 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.74% |
| Mean DD | 4.75% |
| Median DD | 4.29% |
Description: UIMI UBS (Lux) Fund Solutions December 23, 2025
The MSCI Emerging Markets UCITS ETF (XETRA: UIMI) tracks the Morningstar Emerging Markets Total Market Index (TME) in USD, offering investors exposure to a broad basket of equities across developing economies. It is domiciled in Germany, classified as a Global Emerging Markets Equity ETF, and trades under the ticker UIMI on the XETRA exchange.
Key quantitative attributes (as of the latest public filings) include an expense ratio of roughly 0.20% p.a., assets under management near €2 bn, and a top-10 holding concentration of about 15%-dominated by large-cap Chinese and Indian firms. Recent performance has been driven by three macro-level factors: (1) commodity price rebounds that benefit resource-heavy economies, (2) China’s post-COVID growth trajectory, and (3) the U.S. dollar’s relative weakness, which boosts emerging-market earnings when expressed in USD.
If you want a more granular, factor-based analysis of UIMI’s risk-return profile, a quick look on ValueRay can help you validate these insights.
What is the price of UIMI shares?
Over the past week, the price has changed by +0.59%, over one month by +1.66%, over three months by +3.83% and over the past year by +18.21%.
Is UIMI a buy, sell or hold?
What are the forecasts/targets for the UIMI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 128.8 | 8.2% |
UIMI Fundamental Data Overview December 31, 2025
Market Cap EUR = 2.24b (2.24b EUR * 1.0 EUR.EUR)
Beta = 0.0
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.24b EUR (2.24b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 2.24b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 2.24b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 25.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.73% (E(2.24b)/V(2.24b) * Re(6.73%) + (debt-free company))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)